New Route, New Market: Marksans Charts UK Growth with Liquid Gold Formula

Marksans Pharma has received a fresh boost to its UK portfolio with the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) granting marketing authorization for Oxybutynin Hydrochloride Oral Solution. The approval, secured through its UK-based subsidiary Relonchem Ltd, marks a strategic expansion into the urology and neurology therapeutic segments.

 

Key Highlights:

 

The approved product, Oxybutynin Hydrochloride Oral Solution, is used to treat overactive bladder symptoms such as frequent urination, urgency, and incontinence.

This formulation is especially beneficial for pediatric and geriatric patients who face difficulty swallowing tablets.

The approval strengthens Marksans’ liquid dosage portfolio in the UK, following recent authorizations for Metformin Hydrochloride and Gabapentin oral solutions.

Marksans’ UK operations are anchored by Relonchem Ltd, which has been instrumental in expanding the company’s neurology, anti-diabetic, and pain management offerings.

The company’s manufacturing facilities in India, the US, and the UK are approved by top global regulators including USFDA, UKMHRA, and TGA Australia.

This milestone comes amid heightened investor interest, with recent block deals reflecting confidence in the company’s growth trajectory and regulatory momentum.

 

With this latest green light, Marksans Pharma continues to deepen its presence in regulated markets, reinforcing its commitment to accessible, patient-friendly formulations across critical therapeutic areas.

 

Sources: CNBC TV18, Business Standard, Marksans Pharma